TITLE	Supreme Court Decision 2014Hu2702 Decided August 29, 2017¡¼Invalidation of Registration (Patent)¡½ [full Text]
Summary
[1] Requirement for acknowledgement of the nonobviousness of an invention of medicinal use with a specific administration and dosage [2] In the case where Company B filed for a patent invalidation adjudication against Company A¡¯s patent invention under the title of ¡°Pharmaceutical Composition of Phenyl Carbamate for Transdermal Administration¡± on the ground that the nonobviousness of patent claim 1 of the instant patent invention offering new medicinal use via transdermal administration can be denied, the case holding that the lower court erred by misapprehending the legal principle in determining otherwise when in fact the nonobviousness of the instant Claim No. 1 cannot be denied given that the use of transdermal administration is a different effect which a person with ordinary skill cannot anticipate in light of either the level of technological sophistication or the publicly known art at the time of patent application

Prev	Supreme Court Decision 2015Du3867 Decided August 29, 2017¡¼Revocation of Denial of Medical Care Benefits¡½
Next	Supreme Court Order 2017Seu5 Dated August 25, 2017¡¼Support Allowance¡½